Expert Opinion on Pharmacotherapy

Article	Citations
Real-world safety and effectiveness of roxadustat in patients with anemia of chronic kidney disease: interim results from a post-marketing surveillance study in Japan	64
Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond	48
Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy	48
Oral anticoagulation therapy in the setting of liver disease	41
Comprehensive overview of the available pharmacotherapy for the treatment of non-neurogenic overactive bladder in children	41
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis	38
Current treatment options for Mycobacterium marinum cutaneous infections	38
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease	33
The pharmacological treatment and management of hyperhidrosis	31
An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook	28
Pharmacotherapy developments in autophagy inhibitors for bladder cancer	28
Rheumatoid arthritis in Latin America: pharmacotherapy and clinical challenges	26
Thrombopoietin receptor agonists in immune thrombocytopenia: a comparative review of mechanisms, efficacy, and the future of personalized management	26
GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives	26
Antidepressant medications in women aged 40 and older and the risk of fragility fractures: a systematic literature review and meta-analysis	24
Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy	24
How have gamma-secretase inhibitors changed the treatment landscape for desmoid tumors?	23
Current and emerging pharmacotherapies for the treatment of pulmonary arterial hypertension in infants	22
Advances in the management of obstructive hypertrophic cardiomyopathy: The role of mavacamten	22
When is pharmacotherapy necessary for the treatment of seasonal affective disorder?	21
An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma	21
How useful is chemotherapy for atypical and anaplastic meningiomas?	21
Expanding indications and developmental landscape of HER2-targeted therapies in breast cancer: a pharmacotherapeutic perspective	21
Selecting optimal therapy in systemic mastocytosis: current state and future directions	21
Potential treatments for attention-deficit/hyperactivity disorder: a focus on Phase III trials	20

Rise and fall of decongestants in treating nasal congestion related diseases	19
Correction	19
Zanubrutinib for the treatment of chronic lymphocytic leukemia	19
Pharmacologic management of ET: established therapies and emerging agents	19
Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy	18
Current advances in colorectal cancer treatment: a review of recent clinical trials	18
Pharmacotherapy of persistent genital arousal disorder/genito-pelvic dysesthesia: an updated review and data from a registry	18
Momelotinib in myelofibrosis	18
Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis	18
Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy	18
An update on the considerations for patients with rheumatic disease being treated with rituximab during the COVID-19 pandemic and the potential drug treatment strategies	17
A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC)	17
Association between clinical and laboratory factors and response to sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: a retrospective observational study	17
Pharmacotherapy for CD55 deficiency with CHAPLE disease: how close are we to a cure?	17
Pharmacotherapy of treatment-resistant hypertension in patients with chronic kidney disease	17
Evaluating pimavanserin tartrate as a treatment in Parkinson’s disease	16
Effectiveness and safety of oral terbinafine for dermatophyte distal subungual onychomycosis	16
Correction	16
Current pharmacotherapeutic strategies for Strongyloidiasis and the complications in its treatment	16
Recent advances in the treatment of FGFR-altered cholangiocarcinoma	16
The role of pharmacotherapy in the treatment of endometriosis: an update	16
Treating pediatric aggressive behaviors and comorbid conditions	16
Long-acting second-generation injectable antipsychotics for the maintenance treatment of bipolar disorder: a narrative review	15
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature	15
Benefits and disadvantages of combination therapy with imeglimin and metformin in patients with type 2 diabetes	15
Advances in the pharmacotherapeutic management of duchenne muscular dystrophy: an update	15
The role of the D3 dopamine receptor and its partial agonist cariprazine in patients with schizophrenia and substance use disorder	15
Advances in adrenergic receptors for the treatment of chronic obstructive pulmonary disease: 2023 update	15
An update on current pharmacotherapy for vulvar cancer	15
Current pharmacological solutions for Behçet’s syndrome	15
Metabolic dysfunction-associated steatohepatitis treatment: spotlight on the latest hepatoprotective drugs	15
Pharmacotherapy considerations in patients who develop acute kidney injury during anti-cancer therapy	15
Approved medications for opioid use disorder : current update	15
Upadacitinib in Crohn’s disease	15
Tirzepatide for overweight and obesity management	15
An evaluation of the pharmacotherapeutic options for the treatment of adult phimosis. A systematic review of the evidence	14
Pharmacotherapy for cervical cancer: current standard of care and new perspectives	14
Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors	14
Simnotrelvir as a potential treatment for COVID-19	14
Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes	14
Current advancements in pharmacotherapy for cancer cachexia	14
Pharmacogenomics and pediatric drug development: science and political power. A narrative review	14
Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals	13
Optimizing drug therapy for older adults: shifting away from problematic polypharmacy	13
Use of glucagon-like polypeptide 2 analogs for intestinal failure	13
Current and emerging pharmacotherapy for the management of hypertrophic cardiomyopathy	13
Tackling pulmonary fibrosis risks in post-COVID-19: cutting-edge treatments	13
Recent progress in the use of pharmacotherapy for endometrial cancer	13
Pharmacotherapeutic strategies for the treatment of anorexia nervosa – novel targets to break a vicious cycle	13
Antiproliferative therapies in pulmonary arterial hypertension	12

Modern pharmacotherapy guidance for treating alcohol use disorders	12
Current and emerging COX inhibitors for treating postoperative pain following oral surgery	12
Innovative approaches for managing relapsed or refractory peripheral T-cell lymphoma	12
When is pharmacotherapy necessary for Tourette syndrome? The risks vs reward	12
Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper	12
Recent advances in Alzheimer’s disease therapy: clinical trials and literature review of novel enzyme inhibitors targeting amyloid precursor protein	12
Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia	12
An evaluation of pharmacological options for Cushing’s disease: what are the state-of-the-art options?	12
Evidence-based prescribing of medications for ADHD: where are we in 2023?	12
Evaluation of prescribing patterns of switching to and add-on lemborexant in patients treated with hypnotic medication: a nationwide claims database study in Japan	12
Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis	11
Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer?	11
Pharmacotherapy for Gastrointestinal Angiodysplasia: is it effective?	11
The relationship between cognition and the pharmacotherapy of depression	11
An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma	11
Melanoma and pediatric drug development: clinical progress vs. regulatory activism in minors - a narrative review	11
Pharmacological management of pituitary adenomas – what is new on the horizon?	11
A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry	11
New antibiofilm strategies for the management of nontuberculous mycobacteria diseases	11
An overview of emergency pharmacotherapy for priapism	11
Evaluating fostamatinib disodium as a treatment option for immune thrombocytopenia in adult patients	11
Response to the letter to the editor: ‘Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia’	11
Advances in the pharmacotherapeutic management of refractory peptic ulcers	11
Current and emerging pharmacotherapies in Lennox-Gastaut syndrome	11
Recent advances in the pharmacotherapeutic management of diabetic kidney disease	10
Reassessing the role of aspirin in patients with coronary artery disease	10
Current status of intracavernosal injection therapy in erectile dysfunction	10
Is supplemental vitamin D useful in the clinically isolated syndrome (CIS) typical of multiple sclerosis?	10
Longitudinal efficacy of Ertugliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials	10
Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence	10
Auditory toxicity of antimalarials in systemic autoimmune diseases: a systematic review and critical appraisal	10
A review of pharmacokinetic data describing long-acting injectable cabotegravir during pregnancy	10
Migraine in multiple sclerosis patients: potential links and treatment approach	10
Is pharmacotherapy ready to redefine the state of the art in obstructive sleep apnea care?	10
Pharmacological management of digital ulcers in systemic sclerosis - what is new?	10
Evaluating once-weekly insulin efsitora alfa for adults with type 2 diabetes	10
The management of cardiovascular disease risk in patients with rheumatoid arthritis	10
Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date	10
Recently approved and emerging drug options for migraine prophylaxis	10
Perspectives on the current pharmacological strategies for chronic and atrophic gastritis: can more be done?	10
Pharmacological management of gastro-esophageal reflux disease: state of the art in 2024	10
Elinzanetant, a new combined neurokinin-1/-3 receptor antagonist for the treatment of postmenopausal vasomotor symptoms	10
Time to reconsider the way of selecting antihypertensives for hypertensive left ventricular hypertrophy	10
An update on the pharmacological management of acne vulgaris: the state of the art	10
A comprehensive update on the pharmacological management of heterotopic ossification following hip arthroplasty: a level I evidenced based expert opinion	10
Pharmacological and behavioral pain treatment strategies for patients with opioid use disorder	10
Update on current and emerging treatment paradigms for hyperphosphatemia in chronic kidney disease	9
The impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19	9
Pharmacological treatment for children with constipation: present and future	9
Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy	9
Addressing the long-term risks of administering antenatal steroids	9
Promising therapies for the treatment of acromegaly	9
Improving the pharmacotherapeutic treatment of agitation associated with bipolar disorder	9
Clinical, metabolic, and immune interaction between tuberculosis and diabetes mellitus: implications and opportunities for therapies	9
Optimisation of direct-acting oral anticoagulants (DOACs) use for atrial fibrillation (AF) and venous thromboembolism: a practical guide	9
Using sequential pharmacotherapy for the treatment of osteoporosis: an update of the literature	9
Will elinzanetant, a neurokinin receptor antagonist, have a role in the treatment of hot flashes?	9
Risk management of medication errors: a novel conceptual framework	9
Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalization	9
Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review	9
An update on the pharmacotherapy of gout	9
Combining finerenone with SGLT-2 inhibitors: building up CONFIDENCE for the treatment of diabetic kidney disease	9
Clinical guidance for choosing the right pharmacotherapy for migraine attacks	9
Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis	9
Pharmacological management of migraine: current strategies and future directions	9
Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy	9
Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults	9
Effective risk reduction strategies and pharmacological treatment for uncomplicated recurrent urinary tract infections	9
Current and emerging pharmacotherapy for respiratory syncytial virus (RSV) infection in infants	9
Amyloidosis of the heart: pathophysiology, diagnosis, and treatment	9
An update on antifungal resistance in dermatophytosis	9
Upadacitinib in Crohn’s disease: needs more insight	9
Advances in the pharmacological management of acute myeloid leukemia in adults	9
Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?	9
Navigating the liver landscape: upcoming pharmacotherapies for primary sclerosing cholangitis	8
Pharmacological management of heart failure: a patient-centred approach	8
Pharmacotherapy in leishmaniasis: old, new treatments, their impacts and expert opinion	8
Advice and challenges in the pharmacotherapeutic management of diabetic kidney disease in adults	8
New and emerging drugs for the treatment of invasive fungal infections	8
The pharmacological management of treatment-resistant depression: what does the future hold?	8

Impact of bladder cancer family history on the prognosis of patients with non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin (BCG)	8
FGFR inhibitor resistance in cholangiocarcinoma: current understanding and future directions	8
An evaluation of sebetralstat as the first oral on-demand therapy for Hereditary Angioedema	8
Clinical direction in the pharmacological and device management of refractory overactive bladder: the urge to develop new treatments	8
Glasdegib for the treatment of acute myeloid leukemia	8
Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?	8
State-of-the-art and emerging antivirals for chronic hepatitis B infection	8
Making a prescribing choice for rheumatoid arthritis: a focus on small molecule drugs vs. biologics for the most favourable patient outcome	8
Metabolic-associated steatotic liver disease and hepatocellular carcinoma	8
Current and emerging drug strategies for the prevention of venous thromboembolism in acutely ill medical inpatients	8
Identifying the challenges for successful pharmacotherapeutic management of sarcopenia	8
Advances in pharmacotherapy for bronchiectasis in adults	8
Pharmacotherapy options and drug development in bronchiectasis: spotlight on dipeptidyl-peptidase inhibitors	8
Does standard pharmacotherapy still have a major role in the treatment of aggressive B-cell malignancies?	7
Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma	7
Current pharmacological strategies for symptomatic reduction of persistent breathlessness – a literature review	7
Clinical challenges and considerations in pharmacotherapy of osteoporosis due to menopause	7
Novel pharmacotherapy for drug-induced immune hemolytic anemia	7
Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working group	7
Paxlovid as a potential treatment for long COVID	7
Post-surgical pain: evolving drug treatments and challenges	7
Factor VIII stimulants and other novel therapies for the treatment of von Willebrand disease: what’s new on the horizon?	7
Polypharmacology of carbonic anhydrase inhibitors and activators	7
Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature	7
The pharmacological management of alcohol-related cirrhosis: what’s new?	7
Pharmacotherapy for bipolar disorder in adults with high-functioning autism	7
Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?	7
What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis?	7
Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome	7
Montelukast as a potential treatment for COVID-19	7
The current state-of-the-art in pharmacotherapy for pulmonary sarcoidosis	7
How far are we from an approved drug for nonalcoholic steatohepatitis?	7
Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension	7
Venetoclax and new BCL-2 inhibitors in acute myeloid leukemia	7
Oral anticoagulation with versus without antiplatelet therapy in patients with stable coronary artery disease and an indication for anticoagulation: a meta-analysis with trial sequential analysis	7
Pharmacotherapy for gastric and intestinal cramping pain: ‎ current and emerging therapies	7
A systematic review on effect of sodium-glucose cotransporter-2 inhibitors on the metabolic and endocrinological profile of patients with polycystic ovarian syndrome	7
GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients	7
Expert guidance for treating anemia in chronic kidney disease: what is the appropriate drug treatment strategy?	7
Streptozotocin in pancreatic neuroendocrine tumors: a focus on efficacy and safety	7
Liposomal drug formulations for treatment of hematological malignancies	7
Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia	7
Cardio-reno-vascular protection in type 2 diabetes mellitus: new insights into pharmacotherapeutic management	7
An overview of the current drug treatment strategies for moderate to severe, chronic malignant tumor-related pain	7
Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond	7
Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder	6
An update on inclisiran for the treatment of elevated LDL cholesterol	6
BP-lowering effects of SGLT-2 inhibitors and finerenone: an indirect comparison in patients with chronic kidney disease and type 2 diabetes	6
The first five years of SARS-CoV-2: inpatient treatment updates and future directions	6
Hereditary angioedema treatment beyond biologics: current state of preventive and on-demand approaches and new perspectives	6
Intravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions	6
New pharmacotherapies to tackle the unmet needs in bipolar disorder: a focus on acute suicidality	6
An evaluation of the available pharmacotherapy for the treatment of hirsutism	6
An evaluation of sodium zirconium cyclosilicate: a new treatment option for hyperkalaemia in China	6
What are the pharmacological considerations for male congenital hypogonadotropic hypogonadism?	6
What are the challenges in the pharmacotherapeutic management of male genital tuberculosis?	6
Ivosidenib in acute myeloid leukemia	6
Valbenazine for the treatment of chorea associated with Huntington’s disease	6
A Systematic Review on Safety and Efficacy of Migalastat for the treatment of Fabry’s Disease	6
BTK inhibitors in multiple sclerosis: emerging evidence and future directions	6
Evaluating Vonoprazan for the treatment of erosive GERD and heartburn associated with GERD in adults	6
Conditional marketing authorisation of therapeutic medicines for solid tumours in the European Union: methodological and clinical challenges	6
Advances in pharmacotherapy for rosacea: what is the current state of the art?	6
Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors	6
New frontiers in the pharmacological treatment of social anxiety disorder in adults: an up-to-date comprehensive overview	6
Investigating cefepime/taniborbactam for the treatment of complicated urinary tract infections	6
Could protein kinase inhibitors become a next generation pharmacotherapy for non-Hodgkin’s lymphoma?	6
Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4	6
Profiling opnurasib (JDQ-443) for the treatment of non-small cell lung cancer (NSCLC)	6
A systematic review of the effect of semaglutide on lean mass: insights from clinical trials	6
Systemic approaches in biliary tract cancers: a review in the era of multidirectional precision medicine	6
Efficacy and safety of pitolisant in children above 6 years with narcolepsy	6
An update on the pharmacotherapy of osteoporosis	6
Pharmacotherapeutic strategies for Friedreich Ataxia: a review of the available data	6
Advances in pharmacotherapy for the prophylactic treatment of resistant and refractory migraine	6
Opioid MOP receptor agonists in late-stage development for the treatment of postoperative pain	6
Selecting appropriate therapy for cutaneous T-cell lymphomas (CTCLs): recent advances and the unmet need	6
Perspectives on the currently available pharmacotherapy for wet macular degeneration	6
Improving the treatment of Pompe disease with enzyme replacement therapy: current strategies and clinical evidence	6
An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis	6
Current factor IX replacement options for hemophilia B and the challenges ahead	6
The Park Sleep subtype in Parkinson’s disease: from concept to clinic	5
Expanding therapeutic options: overview of novel pharmacotherapies for dyslipidemia	5
Iberogast in functional dyspepsia: yesterday, today, and tomorrow – a narrative review of a multitarget phytomedicine	5
Efficacy and tolerability of pharmacotherapy for obsessive-compulsive personality disorder: a systematic review of randomized controlled trials	5
Advances in drug treatments for mesothelioma	5
Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia	5
Talazoparib for the treatment of prostate cancer	5
Advances in small molecule maintenance therapies for high-grade serous ovarian cancer	5
Testosterone replacement therapy: clinical considerations	5
Highlighting advances on clinical management of pediatric HIV	5
Examining the safety and efficacy of imetelstat in low-risk myelodysplastic syndrome	5
Does varenicline promote abstinence in youths who vape?	5
Current chemotherapeutic options for the treatment of gestational trophoblastic disease	5
Complicated urinary tract infections: an update of new and developing antibiotics	5